Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.32)
# 371
Out of 5,090 analysts
83
Total ratings
55%
Success rate
17.94%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBIO Zenas BioPharma | Initiates: Outperform | $55 | $39.38 | +39.66% | 1 | Nov 26, 2025 | |
| BEAM Beam Therapeutics | Initiates: Outperform | $35 | $27.09 | +29.20% | 1 | Nov 24, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Outperform | $25 | $11.00 | +127.27% | 1 | Nov 20, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $40 | $27.75 | +44.14% | 1 | Nov 18, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $60 → $80 | $65.67 | +21.82% | 1 | Sep 3, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $6.50 | +84.62% | 1 | Sep 3, 2025 | |
| IMNM Immunome | Initiates: Outperform | $18 | $19.76 | -8.91% | 1 | Aug 22, 2025 | |
| SMMT Summit Therapeutics | Maintains: Outperform | $30 → $34 | $18.31 | +85.69% | 2 | Aug 12, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $45.01 | +22.20% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $27.70 | +15.52% | 6 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $185 | $155.51 | +18.96% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $73.64 | -32.10% | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $23.59 | +111.95% | 2 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $110 → $125 | $96.25 | +29.87% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $53.40 | +96.63% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,250 → $1,175 | $718.36 | +63.57% | 5 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $69.56 | +22.20% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $36.38 | +141.89% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $181.30 | +52.23% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $5.13 | +582.26% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $329.89 | -29.67% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $102.52 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $121.22 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $29.52 | -28.86% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $5.30 | +333.96% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $10.89 | +2,195.68% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.40 | +614.29% | 1 | Feb 14, 2018 |
Zenas BioPharma
Nov 26, 2025
Initiates: Outperform
Price Target: $55
Current: $39.38
Upside: +39.66%
Beam Therapeutics
Nov 24, 2025
Initiates: Outperform
Price Target: $35
Current: $27.09
Upside: +29.20%
ORIC Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $25
Current: $11.00
Upside: +127.27%
Upstream Bio
Nov 18, 2025
Initiates: Outperform
Price Target: $40
Current: $27.75
Upside: +44.14%
Cytokinetics
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $65.67
Upside: +21.82%
Vir Biotechnology
Sep 3, 2025
Initiates: Outperform
Price Target: $12
Current: $6.50
Upside: +84.62%
Immunome
Aug 22, 2025
Initiates: Outperform
Price Target: $18
Current: $19.76
Upside: -8.91%
Summit Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $18.31
Upside: +85.69%
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $45.01
Upside: +22.20%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $27.70
Upside: +15.52%
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $155.51
Upside: +18.96%
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $73.64
Upside: -32.10%
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $23.59
Upside: +111.95%
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $96.25
Upside: +29.87%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $53.40
Upside: +96.63%
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $718.36
Upside: +63.57%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $69.56
Upside: +22.20%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $36.38
Upside: +141.89%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $181.30
Upside: +52.23%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $5.13
Upside: +582.26%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $329.89
Upside: -29.67%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $102.52
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $121.22
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $29.52
Upside: -28.86%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $5.30
Upside: +333.96%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $10.89
Upside: +2,195.68%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.40
Upside: +614.29%